The Advanced Regenerative Manufacturing Institute (ARMI) in Manchester will receive up to $51 million over five years to develop an innovative Priority Medicines on Demand project.
According to a joint statement from NH’s Congressional delegation, the project seeks to develop a portable technology that would chemically engineer and produce medications and vaccines to expand access to critical medical care in places where drugs are logistically and financially difficult to deliver. Such areas could potentially include natural disaster areas, locations abroad where service members are deployed and rural areas with limited pharmacy access.
“This is a tremendously exciting project that holds great promise for both the delivery of life-saving medicine and the region’s continued growth as a hub for scientific research and development,” said U.S. Senator Jeanne Shaheen (D-NH). “This investment will provide good-paying jobs in Manchester, further strengthen the economy, and help attract and retain the next generation of innovators. There is so much need in the area of medication delivery and affordability."
“Portable technology that could produce medications and vaccines in hard-to-reach areas could save lives during natural disasters or public health emergencies, such as the current coronavirus pandemic,” said U.S. Senator Maggie Hassan (D-NH). “The Advanced Regenerative Manufacturing Institute in Manchester is helping push the bounds of scientific discovery and improving public health, and I can’t wait to see what comes out of this latest project.”
“As the world grapples with the coronavirus outbreak, it is more clear than ever that investing in biotechnology innovation is critical to the future of health care and building a strong response against health security threats,” said U.S. Rep. Annie Kuster (NH-02). “This project will help bring groundbreaking biotechnology off the sidelines and into medical facilities, create jobs and boost New Hampshire’s economy. I’m excited to support this project and I will continue working to secure crucial resources and funding to help keep Americans safe and protect them from dangerous diseases.”
“I am thrilled to see Manchester continuing to be recognized as a hub of innovation,” said U.S. Rep. Chris Pappas (NH-01). “This project will pioneer life-changing scientific advancements and could change the face of medicine as we know it. By developing the technology to produce medications that would otherwise be inaccessible or not financially feasible, we will be saving lives, improving quality of life, and creating the good, high-paying jobs that will grow our state’s economy.”
ARMI, a bio-research and manufacturing institute located in Manchester, is led by a coalition that includes DEKA Research and Development Corporation, the University of NH and Dartmouth-Hitchcock.